MAPK signaling pathway

Overview

The MAPK signaling pathway is a conserved intracellular signaling network that transduces extracellular and intracellular stimuli into coordinated cellular responses. It is commonly discussed as a family of mitogen-activated protein kinase cascades, including ERK-, JNK-, and p38-related branches, which regulate processes such as cell proliferation, differentiation, stress responses, inflammation, apoptosis, and immune signaling. Because of this broad regulatory role, MAPK signaling is frequently implicated in cancer biology, inflammatory disease, tissue injury, and host defense.

In biomedical research, the pathway is often studied as a mechanistic node linking upstream receptors and stress signals to downstream transcriptional and post-translational responses. In the recent literature provided here, MAPK signaling appears as a target of pharmacologic modulation in psoriasis-like skin inflammation, melanoma cell migration and invasion, immune regulation in triple-negative breast cancer, anti-inflammatory compound screening, cardiovascular injury, and multi-pathway disease models involving NF-κB, PI3K/Akt, JAK-STAT, TLR4, and oxidative stress.

Focus of Latest Publications

Recent publications have examined the MAPK signaling pathway as a mechanistic target in several inflammation- and cancer-related settings. Multiple studies focused on small-molecule or natural-product derivatives with anti-inflammatory activity, including syncarpic acid derivatives, kaempferol, and vasicine derivatives. In these reports, MAPK signaling was assessed alongside cellular assays, Western blotting, RT-qPCR, molecular docking, and in some cases in vivo inflammation models. The overall theme was that suppression or modulation of MAPK pathway activation was associated with reduced inflammatory responses and improved tissue or cell protection.

In inflammatory disease models, syncarpic acid derivatives 5c and 9a showed stronger antioxidant and anti-inflammatory effects than other analogs in RAW 264.7 and BEAS-2B cells, and Western blot analysis indicated that their activity involved modulation of the MAPK signaling pathway. Similarly, bioactive compounds from Angelica dahurica were reported to attenuate LPS-induced inflammation through dual inhibition of MAPK and NF-κB signaling pathways, although the abstract does not provide compound-specific mechanistic details. Vasicine derivative 4r also emerged as a MAPK-targeting anti-psoriatic candidate, reducing imiquimod-induced skin inflammation in vivo and alleviating LPS-induced inflammation in HaCaT cells, with docking studies supporting binding to MAPK protein structures.

MAPK signaling was also implicated in venom-induced cardiac injury and cancer-related signaling. In a study of Nemopilema nomurai venom, the venom activated MAPK signaling in H9c2 cardiomyocytes, increased oxidative stress, and upregulated pro-inflammatory cytokines; kaempferol, identified as the key bioactive component of Modified Huanglian Jiedu Decoction, antagonized these effects by inhibiting MAPK signaling. In hepatocellular carcinoma, a urolithin derivative, compound 11e, inhibited cell migration, induced G2/M arrest, and promoted apoptosis, while network pharmacology and Western blotting supported involvement of the PI3K/Akt and MAPK/ERK signaling axes, including suppression of ERK1/2 phosphorylation.

Another publication described a SIN1-targeting inhibitor that blocked mTORC2- and rapamycin-sensitive mTORC1-mediated signaling and also inhibited wild-type RAS activation and downstream MAPK signaling. This compound reduced proliferation across multiple cancer cell lines and enhanced the efficacy of FDA-approved antineoplastic agents in vitro. Collectively, these recent studies position MAPK signaling as a recurring target in anti-inflammatory, cardioprotective, and anticancer research, often in combination with pathways such as NF-κB, PI3K/Akt, and mTOR-related signaling.